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Abstract 
Background: Glioblastoma is one of the most aggressive cancers of the brain. Malignant traits of glioblastoma cells 
include elevated migration, proliferation and survival capabilities. Galectins are unconventionally secreted glycan-
binding proteins that modulate processes of cell adhesion, migration, proliferation and apoptosis by interacting with 
beta-galactosides of cell surface glycoproteins and the extracellular matrix. Galectin-8 is one of the galectins highly 
expressed in glioblastoma cells. It has a unique selectivity for terminally sialylated glycans recently found enhanced in 
these highly malignant cells. A previous study in glioblastoma cell lines reported that Gal-8 coating a plastic surface 
stimulates two-dimensional motility. Because in other cells Gal-8 arrests proliferation and induces apoptosis, here we 
extend its study by analyzing all of these processes in a U87 glioblastoma cell model.
Methods: We used immunoblot and RT-PCR for Gal-8 expression analysis, recombinant Gal-8 produced in a bacte-
ria system for Gal-8 treatment of the cells, and shRNA in lentivirus transduction for Gal-8 silencing. Cell migration as 
assessed in transwell filters. Cell proliferation, cell cycle and apoptosis were analyzed by FACS.
Results: Gal-8 as a soluble stimulus triggered chemotactic migration of U87 cells across the polycarbonate filter of 
transwell chambers, almost as intensively as fetal bovine serum. Unexpectedly, Gal-8 also enhanced U87 cell growth. 
Co-incubation of Gal-8 with lactose, which blocks galectin–glycan interactions, abrogated both effects. Immunoblot 
showed Gal-8 in conditioned media reflecting its secretion. U87 cells transduced with silencing shRNA in a lentiviral 
vector expressed and secreted 30–40 % of their normal Gal-8 levels. These cells maintained their migratory capabili-
ties, but decreased their proliferation rate and underwent higher levels of apoptosis, as revealed by flow cytometry 
analysis of cell cycle, CFSE and activated caspase-3 staining. Proliferation seemed to be more sensitive than migration 
to Gal-8 expression levels.
Conclusions: Gal-8, either secreted or exogenously enriched in the media, and acting through extracellular glycan 
interactions, constitutes a strong stimulus of directional migration in glioblastoma U87 cells and for the first time 
emerges as a factor that promotes proliferation and prevents apoptosis in cancerous cells. These properties could 
potentially contribute to the exaggerated malignancy of glioblastoma cells.
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Background
Glioblastoma multiform (GBM) corresponds to the high-
est grade (IV) and the most aggressive in clinical course 
among the gliomas, which account for 80  % of primary 
brain tumors [1, 2]. Glioblastoma cells have abnormal 
regulation of growth factor and integrin-mediated signal-
ing pathways, reflected in exaggerated proliferation and 
migration/invasion capabilities, as well as in improved 
survival, avoiding apoptosis under the noxious conditions 
of tumor microenvironment (hypoxia and low nutrients) 
[1, 3–6]. The dismal prognostic of GBM has prompted 
intense research on the molecular basis sustaining these 
malignant traits. Indeed, major advances derive from 
genetic profiles reported by The Cancer Genome Atlas 
Research Network, which revealed recurrent altera-
tions in retinoblastoma signaling, tumor protein 53 and 
receptor tyrosine kinase signaling and are continuously 
being extended to other pathways [5, 7]. However, addi-
tional approaches based on experimental analysis are also 
required [5]. This includes the characterization of GBM 
cell lines attempting to identify factors that underlie their 
exaggerated proliferation, survival and migration pat-
terns in vitro, to then guide in vivo experiments.
Galectins constitute a family of 15 glycan-binding pro-
teins that have been emerging as important modulators 
of a variety of cellular processes relevant to cancer biol-
ogy, including proliferation, survival, apoptosis, migra-
tion and invasion [8–10]. Angiogenesis, tumor immune 
escape and metastasis can compromise the function of 
these lectins [10, 11]. Most galectin actions are exerted 
once secreted by some yet unknown unconventional 
mechanism and involve interactions of their conserved 
carbohydrate-recognition domains (CRDs) with beta-
galactosides contained in the glycans of cell surface 
and extracellular matrix (ECM) components [8–10]. 
Variations in glycan structural complexities determine 
variations in the selectivity of different galectins for 
particular beta-galactoside-containing glycans [8]. As a 
consequence, galectins can play redundant or comple-
mentary functions [10]. Predominant galectin-interact-
ing glycoproteins include integrins at the cell surface and 
laminin and fibronectin in the ECM, crucial in cell adhe-
sion and migration processes [10, 12]. As modulators of 
cell–matrix interactions galectins can enhance or inhibit 
cellular adhesion depending on the biological and physi-
ological context [11].
Galectins 1, -2, -4, -7, -8 and -9 are expressed in human 
brain [13] and Galectin-1, Galectin-3 (Gal-3) and Galec-
tin-8 (Gal-8) are the most abundantly expressed in 
human glioma cell lines [14]. The prototype Gal-1 and 
the chimeric type Gal-3 have been the most studied 
galectins in gliomas and glioblastoma cell lines [12]. The 
expression levels of both Gal-1 [15–18] and Gal-3 [19] 
have been correlated with the more malignant glioma 
tumor grades, although not always for Gal-3 [12, 20, 
21]. The pathogenic roles of these galectins seems to be 
mainly linked to cell migration and invasion, but also to 
chemoresistance [12], and at least Gal-3 can promote 
glioblastoma cells survival under stressing conditions 
[6]. The potential roles of other galectins expressed in 
the brain, specially Gal-8 found in rat and human brain 
[13, 22], remains little explored and even uncertain in cell 
migration [17], and totally unknown regarding prolifera-
tion, apoptosis and survival of glioblastoma cells [12].
Gal-8 is a tandem-repeat galectin consisting of one N- 
and one C-terminal CRD of different glycan selectivity. 
These N- and C-CRDs are spaced by a linker peptide that 
depending on its length gives rise to short and long Gal-8 
isoforms. Gal-8 is unique among other galectins due to 
the particular preference of its N-terminal CRD for α2-3-
sialylated glycans, implying distinct functional conse-
quences [11, 23]. Such property makes Gal-8 especially 
attractive for studies on glioblastoma cells, considering 
the recent evidence of an increased sialylated glycans in 
these cells [24]. Gal-8 interacts with selective β1-integrins 
and with fibronectin, sharing properties with matricellu-
lar proteins [25–28]. As a matrix protein, Gal-8 promotes 
cell adhesion by triggering integrin-mediated signaling 
and cytoskeletal rearrangements [25, 26, 29], which can 
result in increased [25, 26] or arrested cell migration [29] 
depending on the cell type. Gal-8 can also induce cell 
arrest and apoptosis, as reported when it is used as solu-
ble stimulus [27, 30]. Gal-8 has certainly the potential to 
contribute to cancer pathogenesis in different ways. Its 
expression increases in a variety of cancers [11], it can 
stimulate angiogenesis [31, 32] and might promote inte-
grin-mediated metastasis [33]. Gal-8 expression has not 
been found associated with malignancy in gliomas, thus 
contrasting with Gal-1 and Gal-3 [17]. However, Gal-8 
has been described to share with Gal-1 and Gal-3 a pre-
dominant distribution towards the invasive parts of xen-
ografted glioblastomas and, to a lesser extent, also shares 
the stimulation of glioblastoma cell migration when used 
as a matrix protein in a two dimensional in  vitro assay 
[17]. Here we extend the evidence showing a strong role 
of Gal-8 in glioblastoma cell migration, using it as a sol-
uble stimulus on a 3D transwell assay. We also describe 
for the first time that Gal-8 contributes to the prolifera-
tion and anti-apoptotic/survival properties of the highly 
malignant glioblastoma cells.
Methods
Cell lines, antibodies, reagents and plasmids
U87 glioblastoma cells (ATCC) were maintained in Dul-
becco’s Modified Eagle’s Medium (DMEM—4.5  g/l glu-
cose) supplemented with 10 % fetal bovine serum (FBS), 
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100 Units/ml penicillin, 0.1 mg/ml streptomycin (Sigma-
Aldrich, ST Louis, MO) and 5 μg/ml plasmocin. β-actin 
C4 monoclonal (Santa Cruz, Palo Alto, CA, USA) and 
cleaved-caspase-3 rabbit polyclonal antibodies (Cell 
Signaling Technology) were used. We generated recom-
binant human Gal-8 and anti-Gal-8 rabbit polyclonal 
antibodies as described [29, 34]. Lentiviral vectors and 
the viral delivery system for pVSVG, pΔR, and pLKO.1-
puro vectors, the CellTrace CFSE kit for the cell prolifera-
tion assay and Alexa 488-conjugated secondary antibody 
were obtained from (Thermo Fisher Scientific, Waltham, 
MA, USA). Costar Transwell chambers with an 8 μm 
pore polycarbonate membrane and 6.5  mm insert were 
from Corning Incorporated, NY, USA.
Viral particle production and transduction
Recombinant lentiviruses were produced by cotransfec-
tion of HEK293T cells with pVSVG, pΔR, and pLKO. 
1-puro vectors containing Gal-8-specific short hairpin 
RNA (shGal-8) or irrelevant short hairpin RNA (shC) 
as control. The recombinant virus-containing media 
was harvested 24 and 48  h post transfection and used 
for transduction. U87 cells (125,000  cells/well in 6-well 
plates) were grown for 24 h, incubated for 20–24 h with 
recombinant virus-containing medium, and afterwards 
selected using puromycin (1 μg/ml). The cells were then 
amplified in T25 plastic dishes and used within 7  days. 
The entire procedure was repeated for each experiment.
Cell growth assessment with crystal violet assay
Cells were seeded in 96-well plates (1500  cells/well), 
grown for 24  h and incubated for 4  h without serum 
before each treatment. Cell growth was estimated by 
staining the cells with crystal violet as described [29], and 
measuring the 570 nm absorbance, which is proportional 
to cell number [35].
Cell proliferation analysis by flow cytometry
Cell proliferation was assessed with the CellTrace CFSE 
kit that labels free amino groups with the fluorescent 
CFSE die and its dilution after each cell division is ana-
lyzed by flow cytometry [36]. Cells seeded at 200,000 
cells/well in a 6-well plate were incubated after 24 h with 
5 μM CFSE in PBS at 37 °C for 15 min. Then the cells were 
grown in culture medium for 24 h and CFSE fluorescence 
was analyzed using a FACS Verse flow cytometer (BD Bio-
science) using 488 excitation and emission filters. Fluores-
cence was compared with a T0 time point corresponding 
to cells incubated with CFSE and immediately analyzed.
Cell apoptosis
Apoptotic cells were analyzed by both flow cytometry and 
fluorescence microscopy. For flow cytometry, indirect 
immunofluorescence was performed following the stand-
ard protocol for intracellular antigens using the cleaved 
caspase-3 antibody and Alexa 488-conjugated second-
ary antibody. For fluorescent microscopy, the cells were 
grown on coverslips, treated for indirect immunofluo-
rescence with the same antibodies and the apoptotic cells 
were identified by the pattern of caspase-3 activation and 
apoptotic nuclei stained with Hoechst, as described [30].
Migration assays in transwell filters
U87 cells deprived of serum for 4 h were seeded (50,000 
cells) over 8 μm polycarbonate filters of the upper com-
partment of Transwell chambers in DMEM without 
serum. Different conditions were tested comparing the 
effects of DMEM alone (control) or supplemented with 
serum or Gal-8 added to the lower chamber for 16 h at 
37  °C, as described for assaying chemoattractants [37]. 
The cells were stained with 0.2 % crystal violet/50 % etha-
nol for 10 min. Cells at the top side of the upper chamber 
were removed to eliminate background and those that 
migrated to the bottom side of the membrane were pho-
tographed and counted.
Semiquantitative RT‑PCR
Total RNA was purified with TRIzol (Invitrogen) and ana-
lyzed by RT-PCR as described [30], using the following 
primers: 5′-TGACCCAGATCATGTTTGGAG-3′ (sense) 
and 5′-TTCTCCTTAATGTCACGCAC-3′ (antisense) for 
β-actin; 5′-ATACTCTGCTCTATGGCCAC-3′ (sense) and 
5′-TGGCATTTGCATTCACTTCT-3′ (antisense) for Gal-8.
Quantitative RT‑PCR (qRT‑PCR)
The quantification of short and long isoforms of Gal-8 
versus β-actin mRNAs was assessed by quantitative 
PCR (qPCR) in a Rotor-Gene Q from Qiagen, using 
the Rotor-Gene™ SYBR®Green PCR Kit (Qiagen) and 
the following primers: CCAGCTTAGGCTGCCATTC 
(Gal-8S f); AGGCGTGGGTTCAAGTGTAG (Gal-8S r); 
CCCAGCTTCCTAGTAATAGAGG (Gal-8L f); CTTT 
AACGACGACAGTTCGTC (Gal-8L r), TGACCCAGAT 
CATGTTTGAG (human β-actin f ); TTCTCCTTAATGT 
CACGCAC (human β-actin r). The amplification protocol 
was that recommended for the Quiagen Kit.
Cell cycle analysis
Cell cycle was analyzed by flow cytometry (BD FACS-
verse Instrument) using the data acquisition BD FAC-
suite software. Briefly, subsequent to transfections, cells 
were trypsinized, collected into eppendorf tubes, washed 
with PBS by centrifugation at 700g, and fixed in 70  % 
ethanol at −20 °C for at least 2 h, and stored at −20 °C 
until analysis. Cells were then washed again with PBS 
and stained with Propidium Iodide (PI)/RNase Staining 
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Buffer solution (BD Pharmingen) at room temperature 
in the dark, and PI fluorescence was analyzed by flow 
cytometry (protocol as described by BD Biosciences).
Gal‑8 detection
Pull-down of Gal-8 from 72  h conditioned medium of 
U87 cells was used to detect secreted Gal-8. Conditioned 
medium (4  ml) was centrifuged for 10  min at 1000g to 
eliminate cell debris and incubated with 100 μl of α-lactose-
agarose beads for 3 h at 4  °C, in the presence of protease 
inhibitors (2 μg/ml leupeptin, 2 μg/ml pepstatin and 2 mM 
PMSF). Then, the beads were sedimented by centrifugation 
on 1000  rpm for 3 min, washed tree times with PBS and 
subjected to 10 % SDS-PAGE followed by immunoblot with 
anti-Gal-8 (1:500), generated in the laboratory, and a horse-
radish peroxidase-coupled rabbit IgG secondary antibody 
(Rockland), and developed with the enhanced chemilumi-
nescence (ECL) method (Wester Nova 2011) as described 
[29, 34]. Similarly, immunoblot was used to assess Gal-8 
protein levels in cells using 10 μg of total protein lysate. The 
intensity of the bands was quantified using the G:Box gene 
tools software detection system (Syngene). Quantifications 
are relative to actin bands used as a loading control.
Statistics
Comparisons were statistically analyzed with the two-
tailed non-paired Student’s t test.
Results
The human U87 cell line expresses Gal-8 and therefore 
provides a useful model system to study the role of this 
lectin in the proliferation and migration properties of 
highly malignant glioblastoma cells.
Gal‑8 silencing
To study the role of endogenous Gal-8 in migration and 
proliferation processes of U87 cells, we first analyzed the 
effect of silencing its expression with shRNA. We tested 
the silencing potential of two different Gal-8 shRNAs 
(shGal-8#4 and #5) compared with an irrelevant shRNA 
(shC) transduced in lentiviral particles. After 3  days 
post-infection we assessed the expression of Gal-8S and 
Gal-8L isoforms by semi-quantitative RT-PCR (Fig.  1a), 
qRT-PCR (Fig.  1b) and western blot with a polyclonal 
antibody generated in our laboratory (Fig. 1c). hGal-8#5 
silenced around 60  % of both Gal-8S and Gal-8L tran-
scripts, whereas neither shC nor shGal-8#4 had detect-
able effects (Fig. 1a, b). At the protein level, we observed 
about a 60–70 % reduction of Gal-8S protein mass, both 
in the cells and medium (Fig. 1c). Detection of Gal-8 in 
the medium indicates that it is secreted, as previously 
described for Gal-8 and other galectins [11]. We could 
not detect the long isoform by western blot, presumably 
because the longest linker in Gal-8L includes a thrombin 
cleavage site that promotes protein instability [38, 39].
Role of Gal‑8 in U87 cell migration
Gal-8 used as a matrix protein, pre-coating a plastic sur-
face, has been described to stimulate motility of U373 
glioblastoma cells, although to a lesser extent than Gal-1 
and Gal-3 [17]. The assay measured the extent of move-
ment based on the cells’ original position, but did not 
inform about movement directionality required for effec-
tive migration [17]. Here we analyzed the effect of Gal-
8S as a soluble stimulus on three-dimensional (3D) cell 
migration across a polycarbonate membrane of Transwell 
chambers. We seeded the cells in the upper chamber and 
added medium without serum (control), with serum (FBS) 
or with Gal-8S in the lower chamber. This setting is widely 
used to test potential chemoattractants [37], as serum 
added to the upper chamber together with cells does not 
stimulate migration across the filter (not shown). After 
16 h, we stained the filters with crystal violet and counted 









































Fig. 1 Gal-8 silencing in U87 glioma cells. U87 cells were transduced with lentiviral particles containing Gal-8-silencing shRNAs (shGal-8#4 or shGal-
8#5) or irrelevant shRNA (shC). Expression of Gal-8 isoforms (Gal-8S and Gal-8L) was determined 3 days post-infection by semi-quantitative RT-PCR 
(a) qRT-PCR corrected by β-actin mRNA level, (b) and western blot in cell extracts (Cells) and 72 h conditioned medium (Medium) (c)
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the filter. Gal-8S strongly stimulated migration, similar to 
fetal bovine serum (FBS) (Fig. 2a). Co-incubation of cells 
with Gal-8S and 20 mM lactose, used to block the interac-
tions of galectins with cell surface glycans [40], completely 
abrogated the effect of Gal-8S on U87 cell migration. 
These results clearly indicate that Gal-8S acting as soluble 
stimulus promotes migration of U87 cells.
In contrast, we did not observe differences in the 
migration activity of cells transduced with shGal-8#5 
compared with shC (Fig.  2b). As Gal-8 protein is not 
completely silenced, these results suggest that the 
remaining Gal-8 protein (60 %) is enough to maintain cell 
migration.
Role of Gal‑8 on U87 cell proliferation
In addition, we studied the cell proliferation effects 
of recombinant Gal-8S exogenously added to the 
medium. Gal-8S used as a soluble stimulus increased the 
proliferation of U87 cells by 1.5-fold, except when co-
incubated with lactose, as shown by crystal violet stain-
ing (Fig.  3a). These results indicate that Gal-8 acting 
extracellularly on cell surface glycans promotes U87 cell 
proliferation.
We also evaluated the effect of Gal-8 silencing on U87 
cell proliferation counting viable cells stained with trypan 
blue. Two days after plating 100,000 cells, we found that 
U87 cells transduced with an shC increased their cell 
number by 70  %, whereas U87 cells transduced with 
shGal-8#5 only increased their number by 10 % (student 
test; *p < 0.05) (Fig. 3b). These results contrast with those 
we previously showed on cell migration (see Fig. 2b), sug-
gesting that the proliferation process is more sensitive to 
Gal-8 depletion.
To define whether the effect of Gal-8 silencing on cell 
growth was due to reduced proliferation or increased 
apoptosis, we performed FACS analysis with CFSE and 
























































Fig. 2 Soluble Gal-8 as a chemoattractant induces migration of U87 cells, while partial silencing of Gal-8 does not inhibit migration. a U87 cells 
(50,000 per transwell chamber) were seeded in medium without FBS in the upper compartment of transwell chambers and the lower chamber was 
filled with medium in the following conditions: without serum (control), 10 % FBS or 50 μg/ml Gal-8 in the absence or presence of 20 mM lactose 
for 16 h. The bottom sides of the filters were stained with crystal violet to count the cells that migrated across the filter. The graph represents cells 
per field (five different fields in duplicate for each condition) (*p < 0.0001). b Cell migration of U87 cells transduced by control shC or Gal-8-silencing 
sh-Gal-8#5, using 10 % FBS as a chemoattractant, show no significant differences
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activated caspase-3 staining, respectively, and included 
a cell cycle assessment. Taking CFSE fluorescence dilu-
tion as a measure of cell proliferation, we detected an 
almost twofold reduction of cell proliferation in U87 
cells transduced with shGal-8#5, clearly contrasting with 
the shC (Fig. 3c). FACS analysis of the cell cycle showed 
a lower proportion of U87 cells in G0/G1 under Gal-8 
silencing conditions, compared to cells transduced with 
shC (Fig.  4a). Gal-8-silenced U87 cells also showed an 
increased proportion of cells in a Sub-G1 phase, which 
represents fractional DNA that corresponds to apop-
totic cells (Fig.  4a). Flow cytometry (Fig.  4b) and indi-
rect immunofluorescence (Fig.  4c) using antibodies 
against activated caspase-3 also showed higher levels 
of apoptosis in U87 cells silenced with the shGal-8#5. 
These results indicate that endogenous Gal-8 maintains 
high proliferation rates and protects against apoptosis in 
U87 cells.
Discussion
This study complements previous observation regarding 
the role of galectins in glioblastoma cell migration and 
also shows for the first time evidence of a role of Gal-8 
in promoting proliferation and preventing apoptosis of 
these highly malignant cells.
Migration of glioblastoma cells from the initial tumor 
into the surrounding brain parenchyma is a major 
pathogenic characteristic of diffuse GBM tumors, as it 






























































































Fig. 3 Soluble Gal-8S promotes cell growth and its partial silencing reduces proliferation of U87 cells. a Cell growth under Gal-8 treatment. U87 
cells were seeded on plastic plates, treated with soluble Gal-8S (50 μg/ml) for 24 h in the presence or absence of 20 mM lactose and a crystal violet 
assay was performed in triplicate. Gal-8 increased cell growth (*p < 0.0001) except when co-incubated with lactose, indicating a glycan interaction-
mediated effect. b Effect of Gal-8 silencing on cell growth. U87 cells transduced with shGal-8#5 or irrelevant shRNA (shC) lentiviral particles were 
cultivated for 1 week, seeded (100,000 viable cells per well) for 48 h and viable cells were counted after trypan blue staining. Graph represents 
the percentage of cell number increment in two independent experiments in triplicate (*p < 0.01). c Effect of Gal-8 silencing on proliferation. 
Transduced U87 cells were stained with CFSE and fluorescence dilution, reflecting cell proliferation, was analyzed after 24 h by flow cytometry. A 
representative histogram shows a lower decrease of CFSE fluorescence in shGal-8#5 versus control shC-transduced U87 cells. The graph represents 
the quantification of CFSE median fluorescence index of three independent experiments. (*p < 0.05)
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precludes an effective resection and implies post-surgical 
recurrence [4, 41, 42]. Glioma invasion might be a main 
determinant of tumor growth, as predicted by kinetics 
analysis [43–45]. Furthermore, migrating cells seem to be 
more resistant to chemotherapy [4]. Therefore, improv-
ing combat against GBM tumors requires a detailed 
understanding of the cellular and molecular mecha-
nisms and the extracellular factors controlling glioma cell 
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Fig. 4 Gal-8 partial silencing increases apoptosis in U87 cells. a Flow cytometry analysis of cell cycle and fragmented DNA. The histogram shows 
the percentage of U87 cells (transduced with shC or shGal-8#5) in different phases of the cell cycle and the sub-G1 phase containing fragmented 
DNA, indicative of apoptotic cells. The proportion of sh-Gal-8#5-transduced cells compared with shC cells decreased in G0/G1 and G2/M, while 
increased in S and more significantly (sixfold) in Sub-G1. b Apoptosis assessed by caspase-3 activation. U87 cells transduced with shC or shGal-8#5 
and treated for cleaved caspase-3 indirect immunofluorescence were analyzed by flow cytometry (b) a representative dot blot of two experiments 
with the corresponding graph and an histogram of four experiments with an inset graph representing normalized mean fluorescence (MF) intensity 
of cleaved caspase-3 reveals increased apoptosis in shGal-8-#5-transduced cells. (*p < 0.05). c Apoptotic cells detected by indirect immunofluores-
cence against cleaved caspase-3 and Hoechst stained nucleus
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migration [4]. Galectins that modulate cell adhesion and 
migration interacting with integrins and ECM are indeed 
potential factors to consider in a such tumoral trait [12]. 
Previous studies and our present results [17, 46] indicate 
that Gal-8 can play complementary roles, together with 
Gal-1 and Gal-3, in glioma cell migration.
Camby et  al. [17] reported that brain xenographs of 
glioblastoma cell lines H4, U373 and U87 expressed 
higher levels of Gal-1, Gal-3 and Gal-8 in the invasive 
region of the tumor. Nude mice xenographed with U87 or 
U373 cells expressing low levels of galectin-1 (transfected 
with antisense mRNA) survive longer than mice graphed 
with cells expressing normal levels of Gal-1 [46]. These 
observations suggest that galectin-mediated brain inva-
sion contributes to the aggressiveness of these tumors. 
Camby et  al. [17] also described that Gal-1 and Gal-3, 
and to a lesser extent, Gal-8, stimulate glioblastoma cell 
migration in vitro. The migration assay used in that study 
measured two-dimensional motility on a plastic surface 
pre-coated with galectin and did not report direction-
ally of the movement. Instead, we used an experimen-
tal setting described for chemoattractant stimulus of 
cell migration across a polycarbonate filter of transwell 
chambers [37]. We found that Gal-8 as soluble stimuli 
induces a marked trans-filter migration of U87 cells, 
almost as intensively as FBS. Therefore, soluble Gal-8 is a 
very strong stimulus of directional migration in glioblas-
toma U87 cells.
Even though Gal-1, Gal-3 and Gal-8 increase glioblas-
toma cell migration, their experimental silencing has dif-
ferent effects. The migratory activity of A172, U118 and 
U87 glioma cells is reduced upon Gal-1 silencing [47]. In 
contrast, Gal-3 deficiency has been described to increase 
motility in U373 glioblastoma cells cultivated on laminin 
[48]. We show that silencing around 60–70 % of the Gal-8 
protein does not affect the migration activity of U87 cells 
elicited by FBS in the chemotaxis assay. The remain-
ing Gal-8 might be enough to maintain migration, likely 
complementing the roles of Gal-1 and Gal-3, endoge-
nously expressed by U87 cells [17].
Cell migration is a complex process involving protru-
sion of the leading edge, adhesion to the substratum, 
retraction of the rear, and de-adhesion. This process 
involves integrin-mediated cell adhesion to ECM and 
signaling through focal-adhesion-kinase (FAK) and 
Rho-GTPases leading to actin cytoskeleton rearrange-
ments [49–51]. Galectins can stimulate this cell motil-
ity machinery by interacting with integrins [52]. For 
instance, Gal-1-induced migration of glioma cells has 
been associated with modifications to actin cytoskel-
eton organization and the increase in small GTPase 
RhoA expression [46]. Gal-3 can induce actin re-organ-
izations related to cell motility involving EGFR and 
caveolin-1-mediated activation of Rho [53]. Although we 
did not assess here the effects of Gal-8 on these pathways, 
previous studies have shown that Gal-8 used as a matrix 
promotes cellular attachment, spreading, and migration 
by engaging integrin signaling towards FAK, paxillin [26]. 
We described that Gal-8 activates Rho-GTPase Rac-1 
leading to cell spreading and actin cytoskeletal assem-
bly of lamellipodia in Jurkat cells [29]. Therefore, Gal-1, 
Gal-3 and Gal-8 have recognized potential to modulate 
the cytoskeletal machinery that orchestrates cell migra-
tion and can play complementary roles in this process.
In addition, we show that U87 cells respond to exog-
enously added recombinant Gal-8 by increasing their 
proliferation rate. Gal-8 silencing in conditions that 
reduce the mass of Gal-8 protein by 60–70  %, not only 
reduces proliferation but also increases the apoptotic rate 
of these cells. As mentioned, migratory activity of these 
cells remains unaffected under these conditions, suggest-
ing that migration can be maintained at lower levels of 
Gal-8 than those required for proliferation. Our results 
indicate that endogenous Gal-8 expression sustains both 
proliferation and survival of these highly malignant cells.
To our knowledge, this is the first example of tumor cell 
proliferation requiring endogenous Gal-8 expression or 
stimulated by exogenous Gal-8. The only other example 
of Gal-8-induced proliferation is in naïve CD4(+) T cells 
[54]. Previous studies in several cell lines, including the 
human small-cell lung carcinoma cells, reported growth 
arrest and even apoptosis in response to Gal-8 added 
as a soluble stimulus or overexpressed by transfection, 
involving interactions with selected β1-integrins and 
integrin-mediated signaling [26, 27, 55]. Tribulati et  al. 
found that Gal-8-induced apoptosis in a subpopulation 
of CD4(high)/CD8(high) thymocytes [56]. We described 
apoptosis induced by Gal-8 in Jurkat cells and CD3/CD8 
activated human peripheral T cells, involving phospho-
lipase D/phosphatidic acid signaling [30]. Cataneo et al. 
[57] also reported Gal-8-induced apoptosis in activated 
T cells. More recently, Ruiz et al. [58] showed that Gal-8 
inhibits cell proliferation in neuroblastoma, erythroleu-
kemia and colon adenocarcinoma cells. Therefore, Gal-8 
has dual effects, either stimulating or inhibiting prolifera-
tion depending on the cell context.
Downregulation of Gal-1 has been shown to reduce 
proliferation of A172 but not U118 glioblastoma cells 
[47]. However, contrasting with our results in U87 cells, 
recombinant Gal-1 had no effect on the proliferation of 
A172 and U118 cells [47]. U343 cells transfected to over-
express Gal-1 increased their proliferation rates, whereas 
60 % silencing of Gal-1 in U87 cells had no effect on pro-
liferation [59]. It seems that the role of Gal-1 in prolif-
eration depends on intracellular mechanisms whereas its 
role in migration is both intracellular and extracellularly 
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exerted [47]. Gal-3 likely contributes to glioma cell growth 
increasing cell survival in hypoxic and nutrient-deprived 
tumor microenvironments [6]. In U87 cells, Gal-3 knock-
down reduces tumor growth in nude mice without affect-
ing cell proliferation in vitro [6]. Taken together with our 
results, these data suggest that different galectins can 
contribute in different ways to processes of proliferation, 
migration and survival in glioblastoma cells.
We found Gal-8 in conditioned media and show that 
lactose completely blocks the effects of Gal-8 on cell 
migration and proliferation, indicating that U87 cells 
secrete Gal-8 and this lectin modulates these processes 
interacting with cell surface glycans. It is interesting to 
remark that glioblastoma cells have been reported to 
display an increased expression of α2-3-sialyltransferase 
leading to higher terminal sialic acid on glycans [24]. 
Among all other galectins, a unique feature of Gal-8 is the 
strong affinity for α2-3-sialylated oligosaccharides resid-
ing in its N-terminal CRD [60]. Therefore, it is possible 
that Gal-8 plays a major role in glioblastoma malignancy, 
which can be specifically targeted by taking advantage 
of its unique glycan selectivity. Our results support this 
possibility revealing for the first time a role of Gal-8 in 
proliferation, survival and migration in a widely used 
glioblastoma cell model.
Conclusions
Gal-8 has the potential to contribute to the malignancy 
of glioblastoma cells by promoting proliferation, survival 
and migration capabilities. In contrast to other cell sys-
tems, Gal-8 reduces the apoptotic rate in U87 glioblas-
toma cells.
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